Please login to the form below

Not currently logged in
Email:
Password:

biologic

This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

as eczema) - a chronic skin condition characterised by skin blistering, cracking and often debilitating itching - and is the first targeted biologic drug for this purpose.

Latest news

More from news
Approximately 17 fully matching, plus 545 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Jill Ogden has over 30 years of commercial and R&D experience in the biopharmaceuticals and healthcare industries and provides our biologics, early stage deals and platform technologies expertise.

  • The good, the bad and the ugly The good, the bad and the ugly

    Humira is entrenched as a first-line biologic for the treatment of numerous conditions - and despite the EU launch of biosimilars in 2018, we anticipate that it will remain a ... Its revenues grew by a further 9% last year. “A large percentage of this

  • The tipping point The tipping point

    Biologics represent a significant proportion of these innovative medicines and a substantial portion of the global drugs budget. ... In 2016 biologics accounted for 17% of global medicines spend - that’s about 175bn.

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    Biologic or biosimilar: what are prescribers thinking? Biosimilars are raising their competitive game, but are physicians convinced? ... And how do these factors affect the ultimate choice of a biologic vs biosimilar?

  • Pushing the accelerator Pushing the accelerator

    What is the limiting factor? While software can’t speed up the research to develop the molecule or biologic, it can have a significant impact on speeding up the process.

More from intelligence
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 43 partially matching documents found.

Latest from PMHub

  • Webcast: Biosimilars: Friend or Foe to Healthcare?

    Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on

  • Infographic: RA Perceptions

    Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on

  • Biosimilars: Getting the flock to market

    originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.

  • Infographic: PsO market snapshot

    Infographic: PsO market snapshot. An overview of the PsO biologic and systemic patient. ... The snapshot features profile data for patients treated with biologic and systemic agents and looks at disease remission within these patient groups.

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. ... Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents.

More from PMHub
Approximately 7 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics